Clinical Data, Inc. to Present at the 22nd Annual Piper Jaffray Health Care Conference

NEWTON, Mass.--(BUSINESS WIRE)-- Clinical Data, Inc. (NASDAQ: CLDA), today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a Company overview at the 22nd Annual Piper Jaffray Health Care Conference, November 30, 2010 at the New York Palace Hotel, New York, NY. Clinical Data’s presentation will take place at 2:00 p.m. EST.

A live audio and archived webcast of the Company’s presentation can be accessed through Clinical Data's website at www.clda.com.

About Clinical Data, Inc.

Clinical Data develops first-in-class and best-in-category therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases, to be followed by promising drug candidates in major therapeutic areas including oncology and inflammatory diseases. Clinical Data plans to differentiate its therapeutics by combining its drug development and biomarker expertise to develop products with enhanced efficacy and tolerability, improving patient health and reducing costs. To learn more, please visit the Company's website at www.clda.com.



CONTACT:

Clinical Data, Inc.
Theresa McNeely, 617-467-6673
Vice President
Corporate Communications

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Clinical Trials  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.